Faculty profile
Beatrice Setnik
Back to facultyResearch
Read how they describe their research on their University of Toronto profile.
Latest papers
A Pilot, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom.
Journal of clinical psychopharmacology · 2026
The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act.
Psychopharmacology · 2023
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users.
Journal of clinical psychopharmacology · 2022
13 publications.
A Pilot, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom.
Reissig CJ, Chen L, Nallani SC, Hawkins EG, Galati S, Bonson K, Kanumuri SRR, McCurdy CR, Sharma A, Setnik B, Milovan D, Kelsh D, Chiapperino D
The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act.
Moline M, Asakura S, Beuckman C, Landry I, Setnik B, Ashworth J, Henningfield JE
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users.
Landry I, Hall N, Aluri J, Filippov G, Reyderman L, Setnik B, Henningfield J, Moline M
Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users.
Landry I, Hall N, Alur J, Filippov G, Reyderman L, Setnik B, Henningfield J, Moline M
Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate.
Shram MJ, Setnik B, Webster L, Guenther S, Mickle TC, Braeckman R, Kanski J, Martin A, Kelsh D, Vince BD, Barrett AC
Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study.
Landry I, Hall N, Aluri J, Filippov G, Setnik B, Dayal S, Reyderman L, Moline M
Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy.
Setnik B, McDonnell M, Mills C, Scart-Grès C, Robert P, Dayno JM, Schwartz JC
Standardization of In Vitro Testing During Development of Abuse-Deterrent Opioids: Highlights From the Second and Third Category 1 Focus Group Meetings.
Elhauge T, Schwier S, Hoag SW, Setnik B, Bianchi R, Altomare C, Toren P, Lindhardt K
Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
Pathak S, Vince B, Kelsh D, Setnik B, Nangia N, DiPetrillo L, Puhl MD, Sun L, Stanford AD, Ehrich E
Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
Pathak S, Vince B, Kelsh D, Shram MJ, Setnik B, Lu H, Nangia N, Stanford AD, Ehrich E
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.
Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.